Highland Capital Partners, Versant Ventures, jVen capital and CHL Medical Partners also took part in the funding round, which the company said will be used to accelerate the commercialisation of its genome mapping system and other analysis tools.
The company said it hopes to combine human chromosome mapping with next generation genome sequencing to help pinpoint the origins of genetic diseases.
Misti Ushio from Harris & Harris will join the OpGen board of directors as part of the deal.
He said, “For the past several years Harris & Harris Group has been looking for the next transformative technology that goes beyond high-throughput sequencing.
“We are excited to have the opportunity to invest in OpGen, which has launched its Whole Genome Mapping system enabling rapid analysis of structural variation.
“The company has demonstrated commercial success with a proven technology and a growing customer base that includes Wellcome Trust Sanger Institute, The Genome Institute at Washington University, Beijing Genomics Institute and The University of Maryland Institute for Genome Sciences.”
Copyright © 2012 AltAssets